PPAR Research / 2013 / Article / Tab 2

Clinical Study

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Table 2

Plasma lipid levels (mmol/L) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard deviation (in parenthesis).

CKD patientsHealthy reference group
At entryAfter 6 weeksEstimated changeAfter 3 weeks of drugAt entryAfter 6 weeksEstimated changeAfter 3 weeks of drug

Total cholesterol6.4 (1.3)5.7 (1.3)−12%***6.3 (1.2)5.3 (0.7)4.6 (0.5)−14%***5.0 (0.6)
Triglycerides2.0 (1.9)1.2 (0.9)−40%***1.7 (1.1)1.1 (0.4)0.7 (0.3)−34%***1.1 (0.4)
VLDL-cholesterol0.8 (0.4)0.5 (0.3)−40%***0.8 (0.5)0.5 (0.2)0.3 (0.1)−34%***0.5 (0.2)
LDL-cholesterol4.2 (0.81)3.5 (1.2)−21%***4.2 (1.0)3.4 (0.7)2.7 (0.6)−20%**3.1 (0.6)
HDL-cholesterol1.2 (0.2)1.6 (0.4)+24%***1.4 (0.3)1.5 (0.4)1.5 (0.4)+2%1.4 (0.3)

P < 0.01 and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.